The firm invested in Chemclin in 2013 through a consortium led by Actis with China International Capital Corporation (CICC) Private Equity and OrbiMed to acquire a majority stake in the diagnostics company. The post Actis exits Chinese diagnostics business Chemclin for $150m appeared first on DealStreetAsia.